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Generating patient-specific oligodendrocyte progenitors capable of repairing myelination defects observed
in multiple neurological afflictions holds great therapeutic potential. Recently in Nature Biotechnology, Najm
et al. (2013) and Yang et al. (2013) generated these progenitors by direct reprogramming, bringing us closer to
their use in disease analysis and autologous transplantation strategies.The progenitor cells that give rise to
myelin-forming oligodendrocytes of the
central nervous system (CNS), referred
to as oligodendrocyte/type-2 astrocyte
progenitor cells and oligodendrocyte pre-
cursor cells (and here abbreviated as
O-2A/OPCs) have been of great interest
in tissue repair for over 20 years. The initial
demonstration, in 1993, that it was
possible to purify O-2A/OPCs from the
developing rat CNS, expand them exten-
sively in vitro using specific combinations
of mitogens, and then use these cells to
repair demyelinating damage in the spinal
cord (Groves et al., 1993) initiated a multi-
laboratory search for means of devel-
oping these approaches for therapeutic
purposes. Achieving such a goal is partic-
ularly important due to the great range of
neurological afflictions in which myelina-
tion abnormalities occur. Such afflictions
include essentially all traumatic CNS in-
juries (including perinatal birth injuries,
stroke, spinal cord injury, and traumatic
brain injury), a wide range of genetic
leukodystrophies, multiple chronic de-
generative disorders (including multiple
sclerosis, Alzheimer’s disease, and
Parkinson’s disease), affective and neuro-
cognitive disorders (including schizo-
phrenia, depression, and autism), andconsequences of systemic exposure to
multiple chemotherapeutic agents and
environmental toxicants.
The path to myelin repair has included
notable successes in isolating multiple
human cell populations able to generate
oligodendrocytes in genetically hypo-
myelinated shiverer mice, which do not
generate compact myelin due to a muta-
tion in myelin basic protein. Such sources
include human neuroepithelial stem cells,
glial precursor cells isolated from human
embryonic stem cells, and fetal glial pre-
cursor cells isolated from the embryonic
CNS. However, cells derived from these
sources will require coordinate use of
immunosuppressive agents, thus leading
to a need to use reprogramming strate-
gies to enable generation of patient-
specific precursor cells, either through
the generation of induced pluripotent
stem cells (Wang et al., 2013) or through
direct reprogramming to the oligodendro-
cyte lineage.
Direct generation of oligodendrocyte
precursors from autologous cells by
direct reprogramming is a critical next
step in the development of myelination
repair strategies, and two papers in
Nature Biotechnology (Najm et al., 2013;
Yang et al., 2013) bring us much closerto achieving this goal. Two multilabora-
tory teams have used mouse and rat em-
bryonic fibroblasts to directly generate
precursor cells able to mature into oligo-
dendrocytes using combinations of
three transcription factors. In both cases,
induced oligodendrocyte precursors
(iOPs) expressed antigens that are also
expressed by O-2A/OPCs, displayed
similar morphologies and responded to
appropriate mitogens, and showed
appropriate global transcriptional re-
modeling indicative of oligodendrocyte
precursors. The iOPs were induced to
differentiate into oligodendrocytes by
exposure to thyroid hormone or with-
drawal of mitogens and exhibited appro-
priate morphologies and patterns of
antigen expression in vitro. Moreover,
iOPs were able to generate myelin-form-
ing oligodendrocytes when transplanted
into the shiverer mouse CNS.
While the studies converged on two
of the three transcriptional regulators
needed to generate iOPs, they differed
in the cocktail’s third component. Specif-
ically, Olig2 and Sox10, both of which
were previously known to be essential
for oligodendrocyte generation (see
Dugas et al., 2006 and references therein)
were present in both transcription factorll 12, May 2, 2013 ª2013 Elsevier Inc. 503
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Previewsmixtures, but one group identified Zfp536
as the third necessary member (Yang
et al., 2013), while the other (Najm et al.,
2013) identified Nkx6.2.
How far are we from accomplishing this
type of direct reprogramming with human
cells and will human iOPs be as effective
at myelination as precursor cells obtained
directly from the human fetal CNS? The
fact that Olig2 and Sox10 are required in
both cocktails suggests that these will
form the basis for extending this work to
human cells and hopefully will enable
rapid generation of human iOPs. The key
question will then be whether these cells
can outperform progenitor cells isolated
from the human embryonic CNS or gener-
ated from induced pluripotent human
stem cells, which are able to myelinate
the entire mouse CNS when transplanted
in sufficient numbers and locations (Wang
et al., 2013). While the promise of using
autologous iOPs to eliminate the need
for use of immunosuppression is impor-
tant, if these cells are not as competent
at myelinating large regions of the CNS
then more work will be required to
generate progenitor cells with improved
functional properties. As O-2A/OPCs iso-
lated from different regions of the devel-
oping rat CNS have markedly different
capacities to undergo prolonged self-
renewal (Power et al., 2002), attention to
induction of the specific properties shown
by subsets of these cells may be required
to optimize iOP utility.
For all potential oligodendrocyte sour-
ces, it is essential that analysis moves
beyond evaluation in shiverer mice, in
which the CNS lacks the inflammation
and glial scarring that characterizes all
human pathological conditions with the
possible exception of Pelizaeus-Merz-
bacher disease. O-2A/OPCs exposed to
inflammatory cytokines cease division
and differentiate into astrocytes (Tanner504 Cell Stem Cell 12, May 2, 2013 ª2013 Elet al., 2011), and function of these progen-
itors is similarly suppressed by oxidative
stress and by substances expressed in
glial scar tissue (e.g., Franklin and
Ffrench-Constant, 2008). Extrapolation
from the benign shiverer environment to
these more hostile circumstances re-
mains too uncertain to offer unrestrained
confidence in the broad clinical applica-
tion of progenitor cell transplantation
strategies for myelin replacement.
Two further questions, intimately con-
nected to each other, are establishing
the precise identity of the iOPs and deter-
mining their utility in analysis of genetic
diseases characterized by myelination
abnormalities. There are at least two
distinct progenitor cell populations able
to generate oligodendrocytes, these
being O-2A/OPCs and the embryonically
earlier glial-restricted precursor (GRP)
cells. These cells share expression of
several antigenic markers but differ in
substrate and mitogen requirements and
in the types of astrocytes they generate
when exposed to bone morphogenetic
proteins and interleukin-6 family mem-
bers (Noble et al., 2004). Expression of
the O4 antigen by dividing cells gener-
ated by forced expression of Olig2,
Sox10, and Zfp536 (Yang et al., 2013)
would place these cells firmly as classic
O-2A/OPCs. In contrast, cells generated
when Zfp536 is replaced by NKx6.2
were O4 negative (Najm et al., 2013)
and could be an earlier stage of O-2A/
OPC development or could even be
GRP cells. Why might this distinction be
important for using iOPs to study human
disease? One example is provided by
the analysis of Vanishing White Matter
disease (VWMD), which is one of the
most prevalent leukodystrophies and is
characterized by progressive loss of
myelination during early life. Analysis of
glial precursor cells isolated from thesevier Inc.brain of a child with VWMD and grown
in GRP cell conditions showed that a
major defect in these cells lies not in their
ability to generate oligodendrocytes, but
in their ability to generate astrocytes,
suggesting that an important contribution
to this disease of myelin pathology may
be loss of astrocytes as a source of mito-
gens, survival factors, redox support, and
the multiple other functions provided
by these critical support cells (Dietrich
et al., 2005). Regardless of these details,
however, the availability of human iOPs
will greatly accelerate our understanding
of multiple devastating diseases.
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